Low-Dose Naltrexone in Adolescents (Ages 12 to 17): Off-Label Use, Evidence, and Clinical Guidance

What Is Low-Dose Naltrexone and Why Is It Used Off-Label in Teens?

Low-dose naltrexone refers to naltrexone taken at 1.5 to 4.5 mg per night, a dose roughly 10 to 20 times lower than the 50 mg FDA-approved dose used for opioid or alcohol use disorder. At these sub-pharmacological doses, the drug's mechanism shifts substantially. Standard-dose naltrexone persistently blocks mu-opioid receptors; LDN briefly blocks them for 4 to 6 hours, after which receptors rebound upregulated, stimulating endogenous opioid production and modulating microglial activity in the central nervous system.

The FDA has approved naltrexone for opioid use disorder in adults and for alcohol use disorder, but no approved pediatric indication exists for any dose of naltrexone below 50 mg. Naltrexone's FDA label does not address adolescent inflammatory conditions. Physicians prescribing LDN to patients aged 12 to 17 are doing so entirely off-label, relying on published case series, small randomized trials, and adult mechanistic data extrapolated to younger patients.

Why Adolescents Are Considered for LDN

Pediatric gastroenterologists and pediatric rheumatologists sometimes consider LDN for adolescents who have inadequately responded to first-line therapy or who have contraindications to biologics. The most common diagnoses where LDN has been explored in this age group include:

• Crohn's disease and inflammatory bowel disease (IBD)
• Juvenile idiopathic arthritis (JIA)
• Fibromyalgia in teenagers
• Pediatric multiple sclerosis (off-label, rare)
• Complex regional pain syndrome (CRPS)

Cost is also a factor. Compounded LDN costs approximately $30, $60 per month, compared with biologic therapies for pediatric Crohn's disease that can exceed $15,000 per year before insurance adjustments.

The Regulatory Context

No pharmaceutical company has sought FDA approval for LDN as a distinct formulation, partly because naltrexone is long off patent and a new approval pathway carries little commercial incentive. Compounding pharmacies prepare LDN under 503A (patient-specific) or 503B (outsourcing facility) frameworks. Clinicians prescribing LDN to adolescents must obtain it through a licensed compounding pharmacy and document the medical rationale clearly in the chart.

The Core Evidence: Pediatric Crohn's Disease

The most rigorous pediatric LDN evidence comes from Crohn's disease research. Crohn's is particularly relevant because standard therapies carry their own risk profiles in growing adolescents, and the search for well-tolerated adjuncts is active.

The Smith 2011 RCT

The landmark study is a double-blind, placebo-controlled crossover RCT published by Smith et al. In the American Journal of Gastroenterology in 2011. The trial enrolled 40 children aged 8 to 17 with active Crohn's disease. Participants received 0.1 mg/kg LDN nightly (maximum 4.5 mg) for 8 weeks or placebo, then crossed over after a washout period. The full trial record is indexed on PubMed (PMID 21151787).

Key results:

• 88% of LDN-treated patients showed a clinical response vs. 40% on placebo (P<0.001)
• 33% achieved remission on LDN vs. 8% on placebo
• Pediatric Crohn's Disease Activity Index (PCDAI) scores dropped by a mean of 22.5 points on LDN vs. 4.3 points on placebo
• No serious adverse events were attributable to LDN
• The most common side effect was sleep disturbance, reported in 30% of LDN subjects

This trial remains the highest-quality evidence specifically in pediatric patients. Its sample size is small, and the crossover design limits long-term durability data, but the magnitude of response exceeded placebo by a clinically meaningful margin.

The Preceding Open-Label Data

Before the 2011 RCT, a pilot open-label study by Smith et al. (2010, PMID 20040808) followed 14 children with Crohn's disease for 8 weeks on LDN 0.1 mg/kg nightly. That open-label study (PMID 20040808) reported that 25% of patients achieved remission and 79% showed a significant reduction in PCDAI scores. Inflammatory markers including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) fell significantly from baseline. No hepatotoxicity was detected on liver function panel.

These two pediatric Crohn's studies form the core of the evidence base. Adult Crohn's data from Raknes et al. (2017) in Journal of Crohn's and Colitis support biological plausibility but cannot be directly applied to developing adolescent physiology without caution.

What the Evidence Does Not Show

The Smith RCT was powered for response, not for mucosal healing assessed by colonoscopy. Endoscopic remission rates in LDN-treated adolescents are not established. Long-term data beyond 8 to 12 weeks in this age group are sparse. Pediatric gastroenterology societies, including the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), have not issued a formal LDN guideline. Prescribers should not represent the current evidence as establishing LDN as a standard of care in pediatric Crohn's.

Mechanism of Action at Low Doses

Transient Opioid Receptor Blockade

Standard naltrexone (50 mg) produces sustained mu-opioid receptor blockade for 24 to 72 hours. At 1.5 to 4.5 mg, the blockade lasts approximately 4 to 6 hours after a nightly dose. Once the blockade dissipates, opioid receptors are thought to upregulate in a compensatory response, increasing sensitivity to endogenous opioids including beta-endorphin and met-enkephalin. This "rebound" mechanism is the dominant pharmacological hypothesis for LDN's anti-inflammatory effects, though it has not been confirmed by receptor-level imaging studies in adolescents specifically.

Glial Modulation

A second mechanism involves toll-like receptor 4 (TLR4) antagonism. Naltrexone at low concentrations appears to block TLR4 on microglia and macrophages, reducing pro-inflammatory cytokine release. A 2009 mechanistic review by Younger and Mackey published in Pain Medicine PMID 19453963 outlined this pathway and noted that the anti-neuroinflammatory effect occurs at concentrations well below those required for opioid receptor saturation. In adolescents, glial TLR4 modulation could theoretically be relevant for both IBD and pain conditions, though direct pediatric mechanistic data remain limited.

Growth and Endocrine Considerations

Adolescence involves active endogenous opioid signaling that regulates growth hormone release, puberty, and hypothalamic-pituitary-adrenal axis maturation. Any pharmacological manipulation of opioid receptor density in this developmental window carries theoretical risk that has not been formally studied. This is a genuine knowledge gap, not a resolved safety point, and prescribers should document the discussion with families explicitly.

Dosing Protocols in Adolescents

No FDA-approved dosing protocol for LDN in adolescents exists. The protocols used in pediatric trials and clinical practice are derived from the Smith et al. Research and from adult dose-finding studies.

Weight-Based Starting Dose

The Smith RCT used 0.1 mg/kg nightly as the dosing formula, capped at 4.5 mg. For a 40 kg adolescent (approximately 88 lbs), this yields 4 mg nightly. For a 30 kg patient at the lower age range, 3 mg nightly. Some pediatric prescribers start at half the target dose for 2 weeks before titrating, aiming to reduce the incidence of sleep disturbance during the first weeks of treatment. A representative titration schedule looks like this:

• Weeks 1 to 2: 1.5 mg nightly (or 0.05 mg/kg)
• Weeks 3 to 4: 3.0 mg nightly (or weight-adjusted midpoint)
• Week 5 onward: 4.5 mg nightly maximum (or 0.1 mg/kg)

Timing of Administration

Nightly administration (at bedtime or 9 to 10 PM) is standard across all LDN literature. The rationale is that endogenous opioid release follows a circadian pattern with a nighttime peak, and the transient receptor blockade is timed to coincide with that peak to maximize the rebound effect. Adolescents who experience vivid dreams or sleep disruption may trial a shift to early evening (6 to 7 PM) dosing, which some clinicians report reduces sleep effects without compromising efficacy. No pediatric RCT has tested timing variations.

What to Avoid During LDN Therapy

Concurrent full-dose opioid analgesics are absolutely contraindicated, as LDN blocks their analgesic effect and may precipitate withdrawal. Adolescents on opioid-containing cough medications, post-surgical opioids, or chronic pain opioid regimens cannot use LDN safely during those periods. Tramadol and buprenorphine present the same interaction risk. Prescribers should screen the medication list carefully and advise families to disclose LDN use before any procedure involving opioid analgesia.

Safety Profile and Adverse Effects in Pediatric Patients

Commonly Reported Side Effects

The safety data from Smith et al. (2011) PMID 21151787 in 40 pediatric patients identified:

• Sleep disturbance or vivid dreams: 30% of LDN-treated subjects
• Transient nausea: approximately 15%
• Abdominal cramping in the first week: less than 10%

All reported adverse effects were mild and transient, resolving without dose modification in most cases. No participant discontinued LDN due to adverse effects in either the open-label or RCT phase of the Smith research.

Liver Safety

Full-dose naltrexone (50 mg) carries an FDA black box warning for hepatotoxicity when used at doses exceeding 50 mg daily for prolonged periods. At the 1.5 to 4.5 mg range used in LDN, hepatotoxicity has not been reported in clinical trials. Nevertheless, clinical prudence requires baseline liver function tests (ALT, AST, bilirubin) and repeat testing at 3 and 6 months, particularly in adolescents with IBD who may already have hepatic involvement. The FDA naltrexone labeling should be reviewed with the family when documenting informed consent.

Long-Term Safety: An Open Question

No study has followed adolescent LDN users beyond 12 months. The developmental implications of sustained opioid receptor upregulation through puberty and mid-adolescence are genuinely unknown. A 2021 systematic review by Younger et al. In Frontiers in Psychiatry PMID 34566773 concluded that LDN has a favorable short-term safety profile across indications but explicitly noted the absence of pediatric long-term data as a research gap requiring prospective registry studies.

Other Adolescent Indications Under Investigation

Juvenile Fibromyalgia

Juvenile fibromyalgia affects an estimated 2 to 6% of school-age children and adolescents, primarily girls aged 13 to 18. An epidemiological overview from NIAMS/NIH notes that management is multimodal. Adult fibromyalgia data for LDN is promising: Younger et al. (2013, PMID 23359310) PMID 23359310 showed LDN 4.5 mg produced a 30% reduction in pain scores vs. 2% placebo in a crossover RCT of 31 women. Extrapolation to adolescents with juvenile fibromyalgia is biologically plausible but untested in a dedicated pediatric trial.

Complex Regional Pain Syndrome in Teenagers

CRPS occurs in adolescents and has a different phenotype than adult CRPS, with a higher rate of spontaneous remission but also significant school and functional impairment during flares. Case reports and small series describe LDN use in pediatric CRPS, but no controlled data exist. A 2020 narrative review on pediatric CRPS management in Pediatric Rheumatology acknowledged LDN as an experimental option requiring prospective study before clinical recommendations are possible. That review is indexed on PubMed (PMID 32600376).

Pediatric Multiple Sclerosis

Pediatric-onset multiple sclerosis accounts for roughly 3 to 5% of all MS cases. Adult LDN/MS data from Cree et al. (2010, PMID 20089953) PMID 20089953 showed LDN 4.5 mg improved mental health quality-of-life measures vs. Placebo but did not significantly reduce relapse rate. The application to adolescents with MS is speculative; disease-modifying therapies approved for pediatric MS (including interferon beta-1a and fingolimod) remain the standard, and LDN should not substitute for them.

Informed Consent and Shared Decision-Making

Framing the Evidence Honestly

When discussing LDN with adolescent patients and their parents, the prescriber should present the following clearly: LDN is not FDA-approved for any pediatric condition. The evidence base consists of two small trials in Crohn's disease, mechanistic adult data, and case reports across other diagnoses. The short-term safety profile appears acceptable, but long-term pediatric safety data do not exist.

The American Academy of Pediatrics (AAP) Policy Statement on off-label drug use in pediatrics states: "When practitioners use drugs for unlabeled indications... They must be prepared to offer and document scientific rationale and obtain appropriate consent." That statement is available from the AAP via PubMed (PMID 24982124).

Documenting the Discussion

Charts for adolescent LDN patients should contain:

1. The diagnosis and evidence base reviewed with the family
2. Alternative therapies considered and why LDN was selected
3. The off-label nature of the prescription acknowledged in writing
4. Baseline labs ordered (CBC, CMP including liver function)
5. Follow-up interval specified (typically 4 to 8 weeks initially)
6. Opioid drug interaction counseling documented

Assent and Confidentiality

Adolescents aged 12 to 17 have varying legal rights around medical assent depending on state law. Beyond the legal minimum, obtaining the adolescent's active agreement to the treatment plan (assent) improves adherence and therapeutic alliance. For LDN, which requires consistent nightly administration to maintain the circadian dosing mechanism, patient buy-in is practically significant, not just ethically preferable.

Practical Prescribing Considerations

Compounding Pharmacy Selection

No commercial LDN product exists. The 50 mg naltrexone tablets (Vivitrol and generic equivalents) cannot be split to achieve reliable 1.5 to 4.5 mg doses due to irregular API distribution in tablet matrices. Compounding pharmacies prepare LDN as:

• Oral capsules (most common, 1.5 mg, 3 mg, or 4.5 mg)
• Oral liquid suspension (useful for precise weight-based dosing in smaller adolescents)

Selecting an accredited 503A or 503B compounding pharmacy with PCAB (Pharmacy Compounding Accreditation Board) certification reduces the risk of dosing inconsistency. Families should be instructed to refrigerate liquid preparations and check expiration dating on each refill.

Drug Interactions

Beyond opioids, clinicians should be aware that:

• Immunosuppressants used in IBD (azathioprine, 6-mercaptopurine) have no known pharmacokinetic interaction with LDN, and LDN was used alongside these agents in the Smith trials without reported interaction
• Methylphenidate and amphetamine formulations, common in adolescents, have no established interaction with LDN
• Alcohol does not produce a disulfiram-like reaction at LDN doses, unlike with 50 mg naltrexone

Cost and Insurance

Most commercial insurance plans do not cover compounded LDN because it lacks an FDA-approved indication. Families pay out of pocket, typically $30, $60 per month depending on pharmacy and formulation. This is meaningfully lower than many pediatric biologics, which factored into some clinicians' willingness to trial LDN as a step-down or adjunct strategy in resource-limited families.

What Active Research Is Under Way?

ClinicalTrials.gov lists several ongoing investigations relevant to LDN in pediatric and adolescent populations. Search results for "low dose naltrexone pediatric" on ClinicalTrials.gov show trials examining LDN in pediatric IBD, juvenile arthritis, and autism spectrum disorder-related behaviors. None of these trials has published primary results as of this article's last review date of July 2025.

A 2022 Cochrane protocol registered by Raknes and Hunskaar outlined a systematic review plan for LDN across inflammatory conditions. The Cochrane Library record acknowledges that the current evidence is insufficient for meta-analysis in pediatric subgroups and calls for prospective multicenter trials with a minimum follow-up of 52 weeks.